Medacta Group (MOVE) Q4 2025 TU earnings summary

Executive summary

• FY 2025 revenue reached €683.8 million, growing 18.5% in constant currency and 15.8% in Euro, outpacing the market by 4.3x, with strong performance across all business lines and geographies.

• Growth was driven by innovative product launches, personalized medical education, minimally invasive techniques, and significant team expansion, including 258 new hires.

• Acquisition of Parcus Medical in March 2025 strengthened the sports medicine and extremities portfolio, contributing 1.5% to total revenue.

Financial highlights

• Revenue rose to €683.8 million from €590.6 million year-over-year, with 18.5% growth in constant currency.

• All regions contributed: EMEA up 15.2%, North America 19.0%, Asia Pacific 23.0%, and Latin America 42.2%.

• Knee sales surpassed hip sales for the first time, with knees now representing 42% of revenue.

• Extremities business line grew 46.2% in constant currency, the highest among segments.

Outlook and guidance

• FY 2026 revenue growth targeted at 16% to 18% in constant currency, with adjusted EBITDA margin around 28% before currency effects.

• Mid-term (2024-2027E) revenue CAGR expected between 10% and 14%, with adjusted EBITDA margin targeted at 28%.

• Full year audited results to be announced on 13 March 2026.